Latest Cystic Fibrosis Foundation Stories
BALTIMORE, Oct. 21 /PRNewswire/ -- A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI® (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year. The results were presented today at the 24th Annual North American Cystic Fibrosis Conference (NACFC) in Baltimore, Maryland, sponsored by the...
MONMOUTH JUNCTION, N.J., Oct. 21 /PRNewswire/ --Transave, Inc., today reported positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections. The results demonstrate significant clinical benefit and complete the company's Phase II program for the treatment of lung infections due to the bacterium, Pseudomonas aeruginosa in cystic fibrosis...
Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials BETHESDA, Md., Oct. 19 /PRNewswire-USNewswire/ -- In the largest meeting of its kind, nearly 4,000 doctors, scientists, researchers and caregivers will meet in Baltimore, Md., Oct. 21 -23, 2010, to present the latest information and advancements on cystic fibrosis (CF) drug development, research and care. The conference comes at a critical point in the history of cystic fibrosis, a fatal genetic disease that...
Legislation to Help Speed Research for Cystic Fibrosis and Other Rare Diseases BETHESDA, Md., Sept. 23 /PRNewswire-USNewswire/ -- Today the U.S. House of Representatives passed the "Improving Access to Clinical Trials Act" (I-ACT), in a victory for the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations. The bill, which passed the Senate Aug. 5, now goes to President Obama's desk for his signature. He is expected to sign it. This legislation enables...
SOUTH PLAINFIELD, N.J., Sept. 21 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF). The goal of the FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy...
AUSTIN, Texas, Aug. 26 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, today announced the full commercial launch of its xTAG® Cystic Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) (Logo:...
BETHESDA, Md., Aug. 6 /PRNewswire-USNewswire/ -- The U.S. Senate last night passed the "Improving Access to Clinical Trials Act" (I-ACT), a bipartisan piece of legislation championed by the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations. The legislation enables patients with rare diseases to participate in clinical trials without losing eligibility for public healthcare benefits. "We are one step closer to breaking down a serious barrier to...
Kids From 14 States Make Case for Drug Funding and Improved Care for Fatal Disease BETHESDA, Md., June 21 /PRNewswire-USNewswire/ -- Teens from across the United States whose siblings have cystic fibrosis will press their elected officials in Washington, D.C., June 24, to fund drug research and increase access to clinical trials for those with rare diseases. Their goal is to speed the development of new drugs for people who need them most. The teens, ranging in age from 13 to 17 years, will...
MONMOUTH JUNCTION, N.J., June 17 /PRNewswire/ -- Transave, Inc., today reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The data indicated that ARIKACE, delivered once daily for 28 consecutive days followed by 56 days off-treatment for four cycles demonstrated statistically significant improvement in lung function that was sustained during the 56...
Patients Over 40 Once Unheard-of Now a Growing Segment of the PopulationAn emerging population of middle-aged cystic fibrosis patients contains significantly more females and includes a large proportion of patients who lived for decades without a diagnosis or specialized care, according to research published by researchers at National Jewish Health. The comprehensive analysis of this over-40 cohort, published online May 20 in the American Journal of Respiratory and Critical Care, may help...
